Recent data reveals that more Americans are surviving cancer than ever before, reflecting decades of research, early detection, and advanced treatments.
A new report from the American Cancer Society highlights a remarkable shift in cancer outcomes across the United States. According to the annual report released on January 13, approximately seven in ten patients now survive five years or longer following a cancer diagnosis. This figure represents a dramatic increase from the mid-1970s, when only half of diagnosed individuals reached the same milestone. The data analyzed covers diagnoses between 2015 and 2021, and the five-year survival benchmark remains a standard measurement for assessing progress against the disease.
The report also underscores a continued decline in cancer mortality rates through 2023, estimating that nearly 4.8 million deaths have been prevented since 1991. Researchers attribute this decline to reductions in smoking, earlier and more precise detection, and improvements in treatment strategies. Rebecca Siegel, lead author of the report and senior scientific director of surveillance research at the American Cancer Society, emphasized that these outcomes reflect the long-term impact of sustained cancer research efforts. She described the progress as a transformation of many cancers from once-lethal diagnoses into manageable or chronic conditions.
The role of genetics and targeted treatments
Advances in understanding the genetic foundations of cancer have significantly contributed to rising survival rates. Dr. Leonard Kalman, executive deputy director and chief medical officer at Miami Cancer Institute, explains that pinpointing precise genetic mutations within tumors enables physicians to employ precision medicine strategies. “Once a mutation is detected, it can frequently be paired with a targeted therapy that may either cure patients or prolong remission,” Kalman noted. This individualized method is transforming once‑fatal cancers into conditions that can be managed effectively over time, enhancing both life expectancy and overall quality of life for many individuals.
Targeted treatments are increasingly common for cancers such as breast, colorectal, and lung cancers, where molecular profiling guides therapy decisions. Researchers are also expanding the use of immunotherapy, which harnesses the body’s immune system to fight cancer cells, and combination therapies, which pair traditional chemotherapy or radiation with newer drugs. These strategies, combined with early detection through screening programs, have contributed to the substantial gains in survival documented in the report.
Notable improvements in survival for high-mortality cancers
While the overall increases in survival are significant, progress has been especially striking for cancers that were previously associated with low survival rates. Multiple myeloma, a form of bone marrow cancer, has seen five-year survival jump from 32% to 62%. Liver cancer survival has improved from 7% to 22%, and lung cancer rates have risen from 15% to 28%. These improvements illustrate the impact of both scientific advances and public health initiatives aimed at prevention, early diagnosis, and effective treatment.
Despite these positive developments, experts warn that obstacles still exist. Dr. Sara Myers, a breast cancer surgeon and leader of the BRIDGE program at The Ohio State University Comprehensive Cancer Center, explained that although the findings are promising, major gaps in screening and access to care continue. Myers stated, “Ensuring that patients not only benefit from effective treatment but also preserve a strong quality of life by reducing serious side effects is essential.” She stressed that maintaining fair access to care and supportive resources remains vital to sustaining the ongoing rise in survival rates.
Persistent challenges and disparities
Cancer remains one of the foremost causes of death in the United States, with several types proving especially lethal. Lung cancer is expected to lead all cancer-related fatalities in 2026, exceeding the combined death toll of colorectal and pancreatic cancers. Moreover, the prevalence of widespread cancers, such as breast and prostate cancer, continues to grow, emphasizing the ongoing importance of prevention initiatives and early diagnostic measures.
Socioeconomic, racial, and ethnic disparities continue to influence outcomes, with underserved populations often experiencing delayed diagnoses and limited access to advanced treatments. Funding for cancer research, traditionally supported by the federal government, has faced reductions that threaten the sustainability of ongoing studies and the development of new therapies. Shane Jacobson, CEO of the American Cancer Society, warned that setbacks in research funding and health insurance access could undermine progress and slow future breakthroughs.
Dr. Kalman expressed similar worries about potential funding reductions, emphasizing that decades of dedicated investment are only now delivering measurable improvements in patient survival. He noted that “the possibility of undermining this hard-won progress is profoundly troubling.” Ongoing backing for research efforts and fair healthcare policies remains critical to prevent recent survival advances from being lost.
Continued progress and hope
Although obstacles persist, the broader outlook stays encouraging, as advances in genetic science, targeted treatments, immunotherapy, and strengthened public health initiatives are expected to further enhance cancer outcomes. Growing public understanding of preventive steps, from quitting smoking and maintaining a balanced diet to undergoing routine screenings and receiving vaccines against cancer‑related viruses, also supports sustained long‑term progress.
The report emphasizes that the battle against cancer remains ongoing, noting that sustained research funding, broader availability of advanced therapies, and efforts to reduce inequities are vital for continued advancement. For patients and families impacted by the disease, the trends presented in the American Cancer Society report provide encouragement, showing that survival is becoming more achievable and that cancer is increasingly manageable as a long-term condition.
The new findings reflect decades of dedication by researchers, clinicians, and public health advocates to improve cancer outcomes in the United States. With continued investment, innovation, and equitable healthcare access, survival rates are likely to improve further, offering renewed optimism to patients, families, and healthcare providers nationwide.
